Camurus, Lilly enter collaboration pact for long-acting FluidCrystal incretins

Camurus (CAMRF) and Eli Lilly (LLY) have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology. The agreement comprises up to four Lilly proprietary drug compounds. “We are pleased to enter into this collaboration with Lilly to bring innovative long-acting treatment options to people living with obesity, diabetes, and other serious chronic diseases”, said Fredrik Tiberg, President & CEO, CSO of Camurus. “Through the collaboration with Lilly, a global leader in the metabolic disease area, we leverage our FluidCrystal technology in rapidly expanding indication areas impacting hundreds of millions of people, while maintaining our own commercial focus on CNS and rare diseases.” In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to $290M in upfront, development, and regulatory milestone payments as well as $580M in sales-based milestone payments and tiered mid-single digit royalties on global net product sales.